BICSTaR Study: a visual overview

The 12 month results of the Bictegravir Single Tablet Regimen (BICSTaR) study indicate that bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is effective and well tolerated in antiretroviral therapy naïve and experienced persons living with HIV.1a Find out more about the 12 month study results below.